Method
This was a multicentric, prospective study in which pathological stage C patients were centrally randomised 1 : 1 to either no treatment (Group A) or treatment with goserelin acetate 3.6 mg every 28 days (Group B). The 5 y study end point was tumour progression.
Between 1991 and 1994, 201 patients were enrolled in 13 urological centres. All patients were staged according to AUS, and tumour graded according to Gaeta, Mosto® and Gleason. 38% of patients had seminal vesicles invasion and 17% bladder neck involvement. Group B patients started LHRH-analogue treatment within 15 days after RRP. All patients were followed-up to death or 30 May 2000. Tumour progression was de®ned as a PSA increase over 0.5 ng/ml or any local or distant histologically/cytologically proved relapse. DFS was evaluated according to Log Rank Test and Cox.
Results
The main negative predictive parameters were Gleason score (P 0.000) and WHO grade (P 0.005). The DFS curves of Group A and B were signi®cantly different (95% CL) at a median 5 y follow-up, with a 25.2% advantage for Group B over Group A.
Conclusion
Although AT treatment seems bene®cial to all patients with locally advanced prostate cancer at RRP, this advantage is less relevant for the subgroup of patients with Gleason scores 8 ± 10.
